Hemab Therapeutics (NASDAQ:COAG) Major Shareholder Buys $152,973.94 in Stock

Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) major shareholder Ra Capital Management, L.P. bought 6,146 shares of the firm’s stock in a transaction dated Monday, June 15th. The stock was purchased at an average price of $24.89 per share, with a total value of $152,973.94. Following the completion of the purchase, the insider directly owned 6,383,114 shares of the company’s stock, valued at approximately $158,875,707.46. This trade represents a 0.10% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Tuesday, June 16th, Ra Capital Management, L.P. bought 61,523 shares of Hemab Therapeutics stock. The stock was purchased at an average price of $24.98 per share, with a total value of $1,536,844.54.
• On Wednesday, May 20th, Ra Capital Management, L.P. purchased 996 shares of Hemab Therapeutics stock. The stock was bought at an average price of $24.94 per share, with a total value of $24,840.24.
• On Tuesday, May 19th, Ra Capital Management, L.P. purchased 3,802 shares of Hemab Therapeutics stock. The stock was bought at an average price of $24.97 per share, with a total value of $94,935.94.
• On Tuesday, May 12th, Ra Capital Management, L.P. purchased 6,387 shares of Hemab Therapeutics stock. The stock was bought at an average price of $24.90 per share, with a total value of $159,036.30.
• On Monday, May 11th, Ra Capital Management, L.P. purchased 39,869 shares of Hemab Therapeutics stock. The stock was bought at an average price of $24.81 per share, with a total value of $989,149.89.
• On Friday, May 8th, Ra Capital Management, L.P. purchased 1,483 shares of Hemab Therapeutics stock. The stock was bought at an average price of $24.98 per share, with a total value of $37,045.34.
• On Thursday, May 7th, Ra Capital Management, L.P. purchased 9,906 shares of Hemab Therapeutics stock. The stock was bought at an average price of $24.46 per share, with a total value of $242,300.76.
• On Wednesday, May 6th, Ra Capital Management, L.P. purchased 68,018 shares of Hemab Therapeutics stock. The stock was bought at an average price of $24.60 per share, with a total value of $1,673,242.80.
• On Tuesday, May 5th, Ra Capital Management, L.P. purchased 97,411 shares of Hemab Therapeutics stock. The stock was bought at an average price of $24.63 per share, with a total value of $2,399,232.93.
• On Monday, May 4th, Ra Capital Management, L.P. purchased 2,675,000 shares of Hemab Therapeutics stock. The stock was bought at an average price of $18.00 per share, with a total value of $48,150,000.00.

Hemab Therapeutics Stock Performance

Shares of NASDAQ:COAG traded up $0.94 during midday trading on Wednesday, reaching $26.45. The company had a trading volume of 372,565 shares, compared to its average volume of 221,371. Hemab Therapeutics Holdings, Inc. has a one year low of $23.00 and a one year high of $36.61.

Hemab Therapeutics (NASDAQ:COAG) last issued its quarterly earnings results on Thursday, May 21st. The company reported ($23.98) earnings per share (EPS) for the quarter.

Wall Street Analysts Forecast Growth

COAG has been the subject of a number of research reports. The Goldman Sachs Group initiated coverage on shares of Hemab Therapeutics in a report on Tuesday, May 26th. They issued a “buy” rating and a $36.00 price objective for the company. HC Wainwright initiated coverage on shares of Hemab Therapeutics in a report on Wednesday. They issued a “buy” rating and a $40.00 price objective for the company. Jefferies Financial Group initiated coverage on shares of Hemab Therapeutics in a report on Tuesday, May 26th. They issued a “buy” rating and a $39.00 price objective for the company. Evercore initiated coverage on shares of Hemab Therapeutics in a report on Tuesday, May 26th. They issued an “outperform” rating and a $50.00 price objective for the company. Finally, Wall Street Zen raised shares of Hemab Therapeutics to a “hold” rating in a report on Saturday, May 9th. Five research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, Hemab Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $41.40.

About Hemab Therapeutics

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.